Sentences with phrase «cancer gene targets»
An area of long - standing and exceptional strength of the Cancer Center is basic science discovery into novel cancer gene targets and their mechanisms.
https://www.sbpdiscovery.org/ Not exact matches
The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.
'' «At PMV Pharmaceuticals, we are targeting the most frequently mutated gene in human cancer (p53) to make an unprecedented impact on cancer patients» lives.
«The extensive overlap in risk genes for autism and cancer, many of which are chromatin remodeling factors, supports the idea of repurposing epigenetic drugs used in cancer treatment as targeted treatments for autism,» said Yan.
Women with precancer or cancer were most likely to have particular versions of the viral gene E7, which researchers are now interested in targeting.
Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.
Carlo Croce, a cancer researcher at Ohio State University in Columbus, and his colleagues created a diagram of interacting miRNAs for normal body cells by connecting them according to which genes they target and the function of those genes, in a way similar to analyses of human social networks.
The findings by a team of Massachusetts General Hospital (MGH) investigators, which will be published in the April 24 issue of Cell and are receiving advance online release, support the importance of epigenetics — processes controlling whether or not genes are expressed — in cancer pathology and identify molecular circuits that may be targeted by new therapeutic approaches.
Earlier MD Anderson investigations demonstrated exosomes as a factor in detecting pancreatic cancer, but these latest findings reveal genetically altered exosomes as a potentially novel approach for direct and specific targeting of mutated KRAS, the cancer gene commonly linked to pancreatic cancer.
«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»
The researchers found a set of frequently mutated genes in SBAs that could be helpful to clinicians when they are looking to use targeted therapies that work best in cancers with specifics mutations.
Before moving on to human trials, they will need to study all instances of «off - target» effects: Years before Crispr, the viruses employed to deliver DNA in gene therapy trials occasionally damaged the whole system, causing cancer.
«This is a seminal step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer.»
«Researchers have done metabolic studies in patients with adrenal cancer, but they have looked at larger molecules, and they have targeted their investigations at specific steroids or gene profiles.
It turns out that each virus that's been studied and associated with cancer — such as hepatitis B with liver cancer or human papilloma virus with cervical cancer — evolves characteristics that allow it to target those genes immediately upon infection.
«It is exciting to have found a way to selectively target gene delivery to cancer cells,» says Quiñones - Hinojosa.
Unlike whole - genome sequencing, this assay targets a select set of genes or regions with known associations with lymphoid cancer, allowing for more rapid detection of a variety of mutations.
For this study, Dr. Lou and his colleagues focused on triple - negative breast cancer, which is difficult to treat, because it does not exhibit receptors for estrogen, progesterone or the HER - 2 / neu gene, which are targets for many current breast cancer treatments.
Scientists have developed a three - in - one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.
In this research, the group looked at two variants of miR - 21, a microRNA «oncomiR» known to target tumor suppressor genes and which is highly expressed in a number of cancers as well as other proliferative diseases such as psoriasis.
One miRNA can target multiple genes, but their expression is often hijacked by cancer cells and disrupts multiple cancer - causing or tumor - suppressing pathways,» says Shuk - Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.
The researchers say the findings could play an important role in identifying which mutated genes, and which types of cancer, could be targeted to take advantage of the deficiency and ultimately help in treating the cancer.
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — Jcancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).
Rather than target a tumor - suppressor gene directly, Ideker and team took the approach of identifying genetic interactions between a tumor suppressor gene and another gene, such that simultaneous disruption of both genes selectively kills cancer cells.
In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cancer cells.
If we know which genes are responsible for breast cancer, then we can tailor therapies to target those genes specifically.»
Using in vitro, or test tube, experiments, the researchers applied these chemicals to human cancer cells to measure changes of estrogen receptor - and androgen receptor - target genes and transcriptional activity.
Further, a significant percentage of these complex mutations are found in well - known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit.
For example, many of the genes in the new networks are related to cancer, suggesting that certain cancer treatments that target these genes might also be useful to treat ASD.
Despite setbacks in targeting mutant Ras genes, the National Cancer Institute (NCI) recently emphasized the continued importance of this elusive drug target by announcing a focused $ 10 million effort, dubbed the RAS project, to bring together researchers to develop new ideas for blocking Ras.
For instance, researchers used virtual screening to identify compounds that target the gene for PFKFB3, an enzyme that helps regulate the metabolism of cancer cells.
«Research into basic workings of immune system points to way of improving therapies for cancer: Differences in wiring of «exhausted» and effective T cells indicate possible gene - editing targets.»
«The major known cancer driver genes are often mutated in the primary tumor and all metastases, and successfully targeting them in therapy could provide widespread therapeutic benefit,» said Townsend.
This understanding of cancer's evolution has key implications for treatment, he noted, «In addition to pointing out that we will need to target driver genes that are mutated early in cancer, this evolutionary approach provides a method that accurately characterizes which genes are being mutated early and late.
«Gene defect as a potential gateway for targeted prostate cancer therapy.»
«Identifying targets essential to cell survival in tumor suppressor genes has long been an investigational goal with the aim of offering cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature Cancer Biology, MD Anderson president, and senior author for the Nature paper.
By searching for gene deletion patterns in cancer through a concept the investigators call «synthetic essentiality,» the team identified a synthetic essential gene known as chromatin helicase DNA - binding factor (CHD1) as a therapeutic target for prostate and breast cancers lacking a tumor suppressor gene called phosphatase and tensin homolog (PTEN).
Further investigation uncovered CHD1's role as vital to PTEN signaling, and as a potential therapeutic target in prostate and breast cancers with PTEN gene loss.
«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.
«A retrospective analysis of the CHD1 gene in these samples may reveal the potential utility of CHD1 as a biomarker for improved prostate cancer patient stratification and targeted therapy with PARP inhibitors,» notes Johnsen.
Right now, there is no specific treatment for cancers harboring LKB1 or DIXDC1 alterations, but those with a deletion of either gene would likely see results from cancer drugs that target the focal adhesions, says Shaw.
«ALK now becomes the second abnormal gene that we are able to successfully target in lung cancer with drugs other than chemotherapy.»
That change, Kaufman and colleagues found, involves a set of genes that could be targeted to stop cancer from ever starting.
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes.
Dr. Jones obtained his Ph.D. in 2003 from the University of Birmingham Institute of Cancer and Genomic Sciences (United Kingdom) under Professor Lawrence Young, studying the use of gene therapy for targeting Epstein - Barr Virus (EBV) proteins with replication - competent adenoviruses to treat EBV - driven malignancies.
The audience will learn about the current state of breast cancer research, how data generated by NGS gene panels target variants of interest and have been developed and used in routine laboratory research, and the broader issues of breast cancer education, awareness, and community services.
Ras is the most frequently mutated human cancer gene (oncogene), yet despite recent breakthroughs, therapeutic options to target Ras - dependent cancers remain limited.
Many cancer drugs target one of the soldier proteins that have already been expressed from a gene, have received marching orders from other proteins, and are well on their way to causing problems, such as metastasis.
Because immunotherapies are becoming increasingly important for cancer therapy, the investigators examined genes that code for known immune targets to see if any were amplified, which may predict responsiveness to immunotherapy.
In fact, the researchers point out that phase 1 clinical trials are already underway for compounds targeting this gene in other cancers, meaning that the time needed to apply a similar strategy to mucosal melanoma could be dramatically shorter than if they had to start from scratch.